Treatment of Clostridium difficile-associated disease: old therapies and new strategies (Q36240849)

13 August 2017

1 reference

title

Treatment of Clostridium difficile-associated disease: old therapies and new strategies (English)

1 reference

13 August 2017

Clostridium difficile

0 references

author name string

Saima Aslam

series ordinal

1

1 reference

PubMed ID

16122678

13 August 2017

Richard J Hamill

series ordinal

2

1 reference

PubMed ID

16122678

13 August 2017

Daniel M Musher

series ordinal

3

1 reference

13 August 2017

1 September 2005

1 reference

Lancet Infectious Diseases

13 August 2017

1 reference

13 August 2017

5

1 reference

13 August 2017

9

1 reference

13 August 2017

549-557

1 reference

Clostridium difficile: clinical considerations.

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Clinical practice. Antibiotic-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Financial burden of hospital-acquired Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

ANTIBIOTICS, staphylococcal enteritis and pseudomembranous enterocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Staphylococcic enterocolitis. Report of six cases with two fatalities after intravenous administration of N-(pyrrolidinomethvl) tetracycline

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Staphylococcal pseudomembranous enterocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Staphylococcal pseudomembranous enterocolitis complicating treatment with aureomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Pseudomembranous enterocolitis following antibiotic therapy for pneumonia: report of a case

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Staphylococcal and subsequent candida albicans enterocolitis complicating novobiocin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Clindamycin-associated colitis. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Pseudomembranous colitis: Presence of clostridial toxin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Antibiotic-Associated Pseudomembranous Colitis Due to Toxin-Producing Clostridia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

INTESTINAL FLORA IN NEW-BORN INFANTS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Nosocomial acquisition of Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Nosocomial Clostridium difficile colonisation and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Community-acquired Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Epidemiology of community-acquired Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Clostridium difficile--associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment of antibiotic-associated pseudomembranous colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

ORAL ADMINISTRATION OF VANCOMYCIN IN THE TREATMENT OF STAPHYLOCOCCAL ENTEROCOLITIS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Staphylococcal Enterocolitis—Treatment with Oral Vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Oral vancomycin for antibiotic-associated pseudomembranous colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment of Clostridium difficile colitis and diarrhea with vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment of antibiotic-associated colitis with vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Factors associated with failure of metronidazole in Clostridium difficile-associated disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment of Clostridium difficile-associated disease with teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Reduced susceptibility of Clostridium difficile to metronidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Influence of dose and route of administration on disposition of metronidazole and its major metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Intravenous metronidazole for the treatment of Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Failure of parenteral metronidazole in the treatment of pseudomembranous colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

In vitro and in vivo activities of nitazoxanide against Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Nitazoxanide: pharmacokinetics and metabolism in man

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Toxic megacolon complicating pseudomembranous enterocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Comparison of Five Regimens for Treatment of Experimental Clindamycin-Associated Colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Randomized controlled trial of colestipol in antibiotic-associated colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Clostridium difficile diarrhea in patients with AIDS versus non-AIDS controls. Methods of treatment and clinical response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Relapse versus reinfection withClostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

The effect of probiotics on Clostridium difficile diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Epidemiology and prevention of Clostridium difficile infections in a leukemia unit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Control of Clostridium difficile colitis outbreak by treating asymptomatic carriers with metronidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Effectiveness of infection control program in controlling nosocomial Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Acquisition of Clostridium difficile from the hospital environment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Environmental control to reduce transmission of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Favorable Impact of a Multidisciplinary Antibiotic Management Program Conducted During 7 Years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Antibiotic prescribing policy and Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970215-2

7 January 2021

10.1016/S1473-3099(05)70215-2

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16122678